

Material Safety Data Sheet

TNKase(R) Lyophilized Powder (50 mg)

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1. Product identifier

Product name TNKase(R) Lyophilized Powder

(50 mg) CSE-3071

Product code CSE-307

1.2. Relevant identified uses of the substance or mixture and uses advised against

Use - enzyme used as a thrombolytic drug *1

1.3. Details of the supplier of the safety data sheet

Company information Enquiries: Local representation:

Hoffmann-La Roche Inc. 340 Kingsland Street

USA-Nutley, N.J. 07110-1199 United States of America

Phone 001-973/235 50 00 E-Mail info.sds@roche.com

US Emergency phone: (800)-827-6243 US Chemtrec phone: (800)-424-9300

1.4. Emergency telephone number

Emergency telephone number US emergency phone: (800)-827-6243

*1 referring to: Tenecteplase

SECTION 2: Hazards identification

Emergency Overview

Form sterile, lyophilized powder

Color white to off-white

Odor odourless

Date: 23.1.13/LS (SEISMO) Replacing edition of: -- Page: 1/7

Potential Health Effects

- Exposure: Inhalation, Ingestion, Skin contact, Eye contact
- Target Organs: Hematopoietic/blood system, Immune System
- Acute Effects: May cause allergic reactions., This material has not been tested as a whole; therefore, the information described below is based on one or more of its ingredients., This material is not likely to be significantly absorbed via occupational routes of entry due to its chemical structure and large molecular weight., May cause blood system effects.
- Chronic Effects: No adverse effects known
- Carcinogenicity: formulation not listed by NTP, IARC or OSHA

Classification of the substance or mixture / Label elements

Other hazards

Note - no information available

SECTION 3: Composition/information on ingredients

Characterization 0.5 M arginine phosphate buffer is used as a buffering agent to

maintain pH at 7.3.

527 amino acid glycoprotein (enzyme) *1 tissue plasminogen activator (tPA) *1

Ingredients Concentration

Tenecteplase 6.8 %

*1 referring to: Tenecteplase

SECTION 4: First aid measures

4.1. Description of first aid measures

Eye contact - rinse immediately with tap water for 10 minutes - open eyelids

forcibly

- always consult ophthalmologist

Skin contact - remove immediately contaminated clothes, wash affected skin

with plenty of water
- get medical treatment

Inhalation - remove the casualty to fresh air and keep him/her calm

- summon a physician immediately

4.2. Most important symptoms and effects, both acute and delayed

Note - no information available

Date: 23.1.13/LS (SEISMO) Replacing edition of: -- Page: 2/7

4.3. Indication of any immediate medical attention and special treatment needed

Note to physician - treat symptomatically

SECTION 5: Firefighting measures

5.1. Extinguishing media

Suitable extinguishing media - adapt extinguishing media to surrounding fire conditions

Flash point (liquid) not applicable

Unsuitable extinguishing media - full water jet

5.2. Special hazards arising from the substance or mixture

Specific hazards - corrodes metals with formation of hydrogen, which may form

explosive mixtures with air

- heating containers will cause pressure to rise (risk of bursting or

explosion)

- it develops corrosive and irritating vapours, also in case of fire

- formation of toxic and corrosive combustion gases (phosphorus

oxides (eg, phosphorus pentoxide)) possible

5.3. Advice for firefighters

Protection of fire-fighters - precipitate gases/vapours/mists with water spray

- use self-contained breathing apparatus

- chemical incident emergency response unit with full protective

equipment

Special method of fire-fighting - if possible precipitate fire gases with a water jet

SECTION 6: Accidental release measures

6.1. Personal precautions, protective equipment and emergency procedures

Personal precautions - if this is not endangering the action force or other people, ventilate

sewers and cellars

6.2. Environmental precautions

Environmental protection - if possible close leaks

- collect the leaked product by all means available

- if the substance reaches waters or the sewer system, inform the

competent authority

6.3. Methods and material for containment and cleaning up

Methods for cleaning up - collect solids (avoid dust formation) and hand over to waste

removal

Date: 23.1.13/LS (SEISMO) Replacing edition of: -- Page: 3/7

SECTION 7: Handling and storage

7.2. Conditions for safe storage, including any incompatibilities

Storage conditions - below 30 °C

- protected from light

Validity - 8 hours, 2 to 8 °C

*2

 see "best use before" date stated on the label, after opening the content should be used within a short period, any remaining

reconstituted solution should be discarded

Packaging materials - vials

*2 referring to: TNKase reconstituted solution

SECTION 8: Exposure controls/personal protection

8.1. Control parameters

Threshold value (USA) air - STEL: 3 mg/m³ (4 x 15 min)

- ACGIH-TLV: 1 mg/m³

*3

8.2. Exposure controls

Respiratory protection - Respiratory protection is recommended as a precaution to

minimize exposure. Effective engineering controls are considered to be the primary means to control worker exposure. Respiratory protection should not substitute for feasible engineering controls.

 in case of open handling or accidental release: particle mask or respirator with independent air supply

Hand protection - protective gloves (neoprene, nitrile or butyl rubber)

Eye protection - safety glasses

*3 referring to: Phosphoric acid

SECTION 9: Physical and chemical properties

9.1. Information on basic physical and chemical properties

Color white to off-white

Form sterile, lyophilized powder

Odor odourless

Molecular mass ~ 65 kDa *1

Solubility 148'700 mg/l, water (20 °C) *4

Partition coefficient log P_{ow} -4.20 (octanol/water°C) *4

Date: 23.1.13/LS (SEISMO) Replacing edition of: -- Page: 4/7

pH value (20 °C) < 0.5 (100 g/l) *3 (20 °C) 11.4 (100 g/l) *4 7.3 *2

9.2. Other information

Note - no information available

*1 referring to: Tenecteplase

*2 referring to: TNKase reconstituted solution

*3 referring to: Phosphoric acid *4 referring to: L-Arginine

SECTION 10: Stability and reactivity

10.1. Reactivity

Note - no information available

10.2. Chemical stability

Stability - does not contain any antimicrobial preservative; therefore, care

must be taken to ensure the sterility of the prepared reconstituted

solution

- do not freeze the reconstituted solution

10.3. Possibility of hazardous reactions

Note - no information available

10.4. Conditions to avoid

Conditions to avoid - temperatures above 30 °C

- light

10.5. Incompatible materials

Materials to avoid - alkalis (strong exothermic reaction), metals (danger of ignition),

metallic oxides (danger of ignition), nitromethane (risk of explosion)3

10.6. Hazardous decomposition products

Note - not combustible *3

- very hygroscopic *3

*3 referring to: Phosphoric acid

Date: 23.1.13/LS (SEISMO) Replacing edition of: -- Page: 5/7

SECTION 11: Toxicological information

11.1. Information on toxicological effects

Acute toxicity - not bioavailable by oral administration *1

> - LD₅₀ 1'530 mg/kg (oral, rat) *3 - LC₅₀ > 850 mg/m³ (inhal., rat, 1 h) *3 - LD₅₀ 2'740 - LD₅₀ > 5'110 mg/kg (dermal, rabbit) *3

mg/kg (oral, rat)

Local effects - skin: corrosive *3

Sensitization - anaphylactic reactions may occur following the intravenous

application of proteins; rare cases of hypersensitivity have been

described *1

*4

Reproductive toxicity - NOEL (maternal or developmental toxicity) = 5 mg/kg (approx.

8-10 times the human dose) (i.v., rabbit)

referring to: Tenecteplase *3 Phosphoric acid referring to: *4 L-Arginine referring to:

SECTION 12: Ecological information

12.1. Toxicity

Ecotoxicity - moderately toxic for fish (fish, unspecified)

> LC₅₀ 70 mg/l *3

12.2. Persistence and degradability

Ready biodegradability - readily biodegradable *4

12.3. Bioaccumulative potential

Note - no information available

12.4. Mobility in soil

Note - no information available

12.5. Results of PBT and vPvB assessment

Note - no information available

Date: 23.1.13/LS (SEISMO) Replacing edition of: --Page: 6/7

*3

12.6. Other adverse effects

Note - harmful effect due to change of pH

*3 referring to: Phosphoric acid *4 referring to: L-Arginine

SECTION 13: Disposal considerations

13.1. Waste treatment methods

Waste from residues - observe local/national regulations regarding waste disposal

SECTION 14: Transport information

Note - not classified by transport regulations, proper shipping name

non-regulated

SECTION 15: Regulatory information

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

TSCA Status - FDA Exemption - not on inventory

Reporting Requirements - The United States Environmental Protection Agency (USEPA) has

not established a Reportable Quantity (RQ) for releases of this

material.

- In New Jersey, report all releases which are likely to endanger the public health, harm the environment or cause a complaint to the

NJDEPE Hotline (1-609-292-5560) and to local officials.

- State and local regulations vary and may impose additional reporting requirements.

SECTION 16: Other information

Edition documentation - first edition

The information in this safety data sheet is based on current scientific knowledge. It should not be taken as expressing or implying any warranty concerning product characteristics.

Date: 23.1.13/LS (SEISMO) Replacing edition of: -- Page: 7/7